Eli Lilly CEO: Tirzepatide surpassed Keytruda as best-selling drug ever
Dave Ricks · Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing · Sep 29, 2025 · at 3:11
Dave Ricks is the CEO of Eli Lilly. He highlights the sales performance of Eli Lilly's GLP-1 medication tirzepatide relative to Merck's cancer drug Keytruda.
0:00 / 0:12exact quote · 12.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dave Ricks
Eli Lilly CEO Dave Ricks says biotech venture capital is totally broken
“We can talk about venture and biotech in a second because it's totally broken.”
Dave Ricks: Consolidated pharmacy benefit managers make every decision for self-enrichment
“What happened is, you know, the, like any consolidated terminal state of an industry, what's the term, the in-ification of their service, is they just become so, every, every action they make is about their benefit, not the customer.”
Dave Ricks: Fully automated 'in silico' drug discovery is a long way off
“The idea that you're going to throw on, you know, turn a switch on a computer and it's going to think about something and event, you know, the next Prozac. I don't know. I think we're a long way from that day.”
Dave Ricks: Poor US insurance coverage drives patients to gray market GLP-1s
“We're not used to it in the United States. Because we, one, have a, for most people, a pretty good system to subsidize some of the benefit via the insurance markets, so there's not a lot of incentive to go outside the system. That's different for these drugs, …”
Dave Ricks: Competitors cannot match our manufacturing scale without Chinese state backing
“And unless some Chinese state-owned enterprise gets in this business, it'll be very hard for others to build that out and follow.”
Dave Ricks: Chinese entities use AI to reverse-engineer and hack chemical patents
“China's getting very good at patent hacking. So what they do is they look at that chemical structure. They work backwards, sometimes driven by AI. Algorithms define chemical structures that will behave similarly, but are outside the patent scope, and they go f…”